Sinopharm’s Wuhan affiliate boosts COVID-19 shot annual capacity to 1 bln doses

Published: Updated:
Read Mode
100% Font Size
2 min read

A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.

The Wuhan Institute of Biological Products made the announcement in a statement released late on Monday through social media. It did not specify when it will operate the factory at full capacity.

For more coronavirus news, visit our dedicated page.

Still, the announcement marks a step toward state-backed Sinopharm’s annual capacity target of 3 billion doses for its COVID-19 vaccines.

The Beijing Institute of Biological Products, another Sinopharm affiliate whose shot gained emergency-use approval from the World Health Organization, has a factory with annual capacity of 1 billion doses and is also building a new facility.

China has approved four COVID-19 vaccines from domestic makers Sinopharm, Sinovac Biotech Ltd and CanSino Biologics Inc for general public use, and three other vaccines for emergency use.

For all the latest headlines follow our Google News channel online or via the app.

Sinovac, whose COVID-19 vaccine capacity is 2 billion doses per year, on Tuesday said it has supplied over 600 million doses at home and abroad as of the end of May.

Read more:

Sinopharm vaccine: Chinese scientists publish world’s first report on clinical trials

Indonesia study finds China’s Sinovac vaccine highly effective in health workers

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

Top Content Trending